

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/136426/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Short, Emma, Thomas, Laura E. , Davies, Alice, Bolton, Alice, Maynard, Julie, Giles, Peter , Mort, Matthew , Consoli, Claudia, Egner, Iris, Jundi, Hala and Sampson, Julian R. 2020. APC transcription studies and molecular diagnosis of familial adenomatous polyposis. *European Journal of Human Genetics* 28 (1) , pp. 118-121. 10.1038/s41431-019-0486-2

Publishers page: <http://dx.doi.org/10.1038/s41431-019-0486-2>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



APC Transcription Studies and Molecular Diagnosis of Familial Adenomatous Polyposis

Emma Short^{1*, 2}, Laura E. Thomas¹, Alice Davies¹, Alice Bolton¹, Julie Maynard¹, Peter
Giles¹, Matthew Mort¹, Claudia Consoli¹, Iris Egner¹, Hala Jundi¹, Julian R. Sampson¹

1. Institute of Medical Genetics, Division of Cancer and Genetics, Cardiff
University School of Medicine, Cardiff CF14 4XW, UK

2. Department of Cellular Pathology, University Hospital of Wales, Heath Park,
Cardiff, CF14 4XW, UK

*Correspondence to Emma Short at Division of Cancer and Genetics, Cardiff University
School of Medicine, Heath Park Campus, Cardiff, CF14 4XW, UK. shorte@cardiff.ac.uk,
02920748170

Running Title: APC Transcription Studies in FAP

Conflict of Interest

There are no conflicts of interest to declare

20

21 **Grants**

22 This work was supported by grants from The Pathological Society of Great Britain and
23 Ireland and from Health and Care Research Wales to the Wales Gene Park and Wales
24 Cancer Research Centre.

25

Abstract

Familial Adenomatous Polyposis (FAP) is characterised by the development of hundreds to thousands of colorectal adenomas and results from inherited or somatic mosaic variants in the *APC* gene. Index patients with suspected FAP are usually investigated by *APC* coding region sequence and dosage analysis in a clinical diagnostic setting. The identification of an *APC* variant which affects protein function enables predictive genetic testing to guide the management of family members. This report describes a 4-generation family with a phenotype consistent with FAP, but in which an *APC* variant had not been identified, despite testing. To explore this further, quantitative PCR (qPCR) was employed to assess *APC* transcription, demonstrating reduced levels of *APC* RNA. Next generation sequencing (NGS) identified the *APC* 5'UTR/ Exon 1 variant, c.-190 G>A, that had been reported previously in another FAP family with *APC* allelic imbalance. Quantitative RNA studies and DNA sequencing of the *APC* promoters/ Exon 1 may be useful diagnostically for patients with suspected FAP when coding region variants cannot be identified.

Key Words

- Colorectal adenomas
- Colorectal polyposis
- Familial adenomatous polyposis
- *APC*
- Quantitative Polymerase Chain Reaction (qPCR)

Introduction

Familial Adenomatous Polyposis (FAP), due to germline or somatic mosaic variants affecting *APC*, is the second most common cause of inherited colorectal cancer (CRC) after Lynch Syndrome. FAP affects approximately 1 in 8000 individuals (reviewed in ref 1; reviewed in ref 2; reviewed in ref 3). It is characterised by the development of hundreds to thousands of colorectal adenomas and, if untreated, will progress to CRC. In addition to FAP, there are several other, rarer syndromes which are characterised by multiple, though usually fewer, colorectal adenomas and an increased risk of CRC. These include *MUTYH*-Associated Polyposis (MAP) (ref 4), Polymerase-Proofreading Associated Polyposis (PPAP) (ref 5), *NTHL1*-Associated Polyposis (NAP) (ref 6) and *MSH3*-Associated Polyposis (ref 7).

The identification of causative variants in families with inherited polyposis syndromes is important for the prevention of CRC. Good clinical practice includes referral of patients with multiple colorectal adenomas for genetic counselling and consideration of diagnostic testing of *APC* and other polyposis genes. Well over 90% of patients with a phenotype of classical FAP have a germline *APC* variant affecting protein function identified through sequencing of coding exons and deletion/duplication analysis via multiplex ligation-dependent probe analysis (MLPA) (ref 8). Of those patients with an attenuated phenotype, with <100 adenomas, *APC*, *MUTYH* or other causative germline variants are detected in only 20-50% of cases (ref 8). The monogenic mechanisms potentially operating in the group who have no *APC* variant identified (NVI) include

promoter and other non-coding variants, somatic mosaicism, the involvement of other genes and epigenetic effects.

This paper describes a 4-generation family with a clinical diagnosis of FAP. Despite genetic diagnostic testing performed in several expert centres, the genetic basis for the disease had not been determined.

Methods

Subjects

A study at Cardiff University, 'Genetic Mechanisms in Colorectal Polyposis' (approved by the NHS Research Ethics Committee for Wales: REC 3, study 12/WA/0071) is currently investigating patients with at least 10 colorectal polyps who have no pathogenic *APC* variant identified (NVI) on genetic testing in a clinical diagnostic setting. All patients recruited to the study give written, informed consent.

One of the probands (Individual 2.1, Figure 1) participating in the study was a 44-year old female who had undergone a colectomy and proctectomy for clinical FAP. At least 11 other family members were also affected (Figure 1). The family history was provided by recruited family members but detailed clinical information on other family members was not available.

90

91 [Quantitative PCR \(qPCR\)](#)

92 *APC* transcript levels in leukocyte RNA were first determined within a healthy control
93 cohort. RNA was prepared from venous blood samples from 40 normal controls,
94 including 7 unaffected adult relatives of NVI patients and 33 healthy individuals
95 without a personal or family history of polyposis or CRC recruited through a local
96 study: Causes of Bowel Polyps: Recruitment of Healthy Controls (approved by Cardiff
97 University School of Medicine Ethics Committee). RNA was converted to cDNA, which
98 underwent qPCR using Taqman technology (details of experimental protocols are in
99 Supplementary 1 and 2, available at the European Journal of Human Genetics
100 webpage). cDNA from Individual 2.1 underwent qPCR using the same methods, along
101 with a positive control with FAP due to a previously characterised *APC* promoter
102 deletion that abrogated transcription, FAP1. Results were analysed using
103 ThermoFisher Cloud software, and *APC* expression levels in Individual 2.1 and the FAP
104 positive control were compared to the healthy cohort to give an Rq value.

105

106 [Ultra-Deep Sequencing \(UDS\), Variant Calling and Validation in DNA](#)

107 UDS across the whole genomic locus of *APC*, hg19 chr5:g.112042936-112186350, was
108 undertaken in genomic DNA extracted from whole blood from Individual 2.1.
109 Reference sequence NM_001127511.2 was used, and the first delimited exon, which is
110 untranslated, was assigned as Exon 1.
111 Target sequence capture was undertaken using the Haloplex assay (Agilent).
112 Sequencing was performed by the Wales Gene Park Genomics Facility

(<http://www.walesgenepark.cardiff.ac.uk/next-generation-sequencing/>) using the HiSeq (Illumina). Rare variants, present in $\leq 1\%$ of the population, according to dbSNP data or The 1000 Genomes Project data, were analysed using CADD software (<http://cadd.gs.washington.edu/home>) and were assessed using the Integrative Genomics Viewer (IGV) (<https://www.broadinstitute.org/igv/>). Variants which had a CADD score ≥ 15 were validated with Sanger sequencing (details in Supplementary 3, available at the European Journal of Human Genetics webpage).

Results

qPCR Studies

The *APC* Rq value for FAP1 was 0.48 and for Individual 2.1 it was 0.56 (Mean delta Ct = 8.238). An assessment for *APC* allelic imbalance in Individual 2.1 was attempted but homozygosity for the chosen SNPs in her genomic DNA precluded informativity of the analysis.

The qPCR results for all controls and NVI polyposis patients are in Supplementary 4, available at the European Journal of Human Genetics webpage. A further 3 NVI polyposis patients also had apparently reduced *APC* expression, but the cause in these patients was not identified despite *APC* ultradeep sequencing, karyotype analysis where possible and *APC* promoter methylation studies.

APC Capture and Ultra-Deep Sequencing (UDS)

The mean depth of coverage across the *APC* locus for Individual 2.1 was 2458 reads, with 97.7% of the target region covered at a minimum of 1x read and 73.4% at a

minimum of 1000x reads. The *APC* promoter/Exon1 variant c.-190 G>A (hg19 chr5:g.112043225 G>A) was identified in 2845/5546 (51%) reads and confirmed by Sanger sequencing. It had a CADD score of 22.4. The proband's father and one cousin, both of whom also had a clinical diagnosis of FAP, were subsequently recruited for investigation (Figure 1 Individuals 1.1 and 2.2). Both were found to carry the c.-190 G>A variant. qPCR studies gave Rq values of 0.56 for the father and 0.63 for the cousin. The variant has been submitted to the LOVD database (patient ID 00213111).

Discussion

Li *et al* (2016) (ref 9) previously reported the *APC* c.-190 G>A variant in another family with FAP and profuse fundic gland polyposis, in which 5 individuals were affected over 3 generations. The authors performed electromobility shift assays showing that the variant led to reduced protein binding, and that the protein likely to be affected was the transcription factor YY1. They demonstrated allelic imbalance of *APC* expression in carriers of the variant due to abrogation of transcription.

This is consistent with the observation that truncating *APC* germline mutations usually do not result in nonsense mediated decay (NMD) (ref 10, reviewed in ref 11) so when reduced *APC* expression is identified, it may be more likely to result from reduced transcription caused by promoter alterations rather than a 'missed' truncating variant.

In Li's paper, other specific germline point mutations in the *APC* promoter 1B region resulted in a phenotype of gastric polyposis. Individual 2.1 was found to have 'multiple

fundic gland polyps in the body and fundus' when she attended upper gastrointestinal endoscopic surveillance, but details of upper GI endoscopy could not be obtained for other family members.

The variant has been categorised as 'disease causing' (HGMD Accession CR165704) and predictive genetic testing is now being offered to relatives of Individual 2.1.

Our findings suggest that quantification of *APC* transcription may help to direct the search for an unusual underlying genetic mechanism in NVI patients with colorectal polyposis.

Other studies have also demonstrated the importance of analysing transcripts in the search for unusual underlying mechanisms in NVI polyposis patients. As early as 1993, Powell *et al* (ref 12) used an allele-specific expression assay to show that 3/11 *APC* NVI patients with clinical FAP had significantly reduced expression of one *APC* allele. In 1999 Laken *et al* (ref 13) used monoallelic mutation analysis (MAMA) to reveal that 7/9 *APC* NVI patients had reduced/ no expression from one of their *APC* alleles. More recently Yan *et al* (ref 14) identified a patient with colorectal tumours and reduced levels of the *APC* protein. This patient had the expected 50:50 *APC* allelic ratio in gDNA, but a 66:34 *APC* allelic ratio in cDNA from lymphoblastoid cells (ref 14). Early findings regarding *APC* AI have been supported by Castellsagué *et al* (ref 15). Of 23 *APC*/*MUTYH* NVI polyposis families who were heterozygous for the SNP rs2229992, 2 were shown to exhibit *APC* AI. The AI in one family was suggested to result from

promoter variants (ref 15). In 2012 transcript analysis in a sample of 125 NVI polyposis patients found that 8% had a reproducible aberrant transcript pattern, the majority of which reflected insertions between two exons originating from exonised sequences deep within the corresponding intron (ref 8).

Considering *APC* qPCR studies, a rigorously determined Rq threshold would be required for diagnostic translation of transcription assays. With whole genome sequencing emerging as a realistic basis for genetic diagnosis it is likely that many more potentially regulatory non-coding variants will be identified in future. In this case, transcription studies and/or transcript analysis might form a second line test to provide evidence for or against their pathogenicity.

Conflict of interest

There are no conflicts of interest to declare.

References

1. Mishra, N. and Hall, J. Identification of patients at risk for hereditary colorectal cancer. *Clin Colon Rectal Surg* 2012 25(2): 67-82.
2. Fearnhead, NS, Wilding JL, Bodmer WF. (Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. *Br Med Bull* 2002 64: 27-43.
3. Bodmer, W. (Familial adenomatous polyposis (FAP) and its gene, APC. *Cytogenet Cell Genet* 1999 86: 99–104.
4. Al-Tassan, N, Chmiel NH, Maynard J. *et al* Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors. *Nat Genet* 2002 30(2): 227-232.
5. Palles, C, Cazier, JB, Howarth, KM. *et al* Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. *Nat Genet* 2013 45(2): 136-144.
6. Weren, RD, Ligtenberg MJL, Kets, CM. *et al* A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. *Nat Genet* 2015 47(6): 668-671.
7. Adam, R, Spier, I, Zhao, B. *et al* (Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. *Am J Hum Genet* 2016 99(2): 337-351.
8. Spier, I, Horpaopan, S, Vogt, S. *et al* (Deep intronic APC mutations explain a substantial proportion of patients with familial or early-onset adenomatous polyposis. *Hum Mutat* 2012 33(7): 1045-1050.

9. Li, J, Woods, SL, Healey, S. *et al* Point mutations in exon 1B of APC reveal gastric adenocarcinoma and proximal polyposis of the stomach as familial adenomatous polyposis variant. *Am J Hum Gen* 2016 98(5): 830-842.
10. Miyoshi, Y, Nagase, H, Ando, H. *et al* Somatic mutations of the APC gene in colorectal tumours: mutation cluster region in the APC gene. *Hum Mol Genet* 1992 1(4):229-233.
11. Jopling. CL. Stop that nonsense. *eLife* 2014 3:e04300.
12. Powell, SM, Petersen, GM, Krush, AJ. *et al* Molecular diagnosis of familial adenomatous polyposis. *N Engl J Med* 1993 329(27), pp. 1982-1987.
13. Laken, SJ, Papadopoulos N, Petersen GM. *et al* Analysis of masked mutations in familial adenomatous polyposis. *Proc Natl Acad USA* 1999 96(5), pp. 2322-2326.
14. Yan, H, Dobbie, Z, Gruber, SB.*et al* Small changes in expression affect predisposition to tumorigenesis. *Nature Genetics* 2002 30, pp. 25-26.
15. Castellsagué E, González, S, Guinó, E, *et al* Allele-specific expression of APC in adenomatous polyposis families. *Gastroenterology* 2010 139(2), pp. 439-447.

242

243


244 Figure legends

245 Figure 1 Family Pedigree. Proband is marked by an arrow (2.1)

246

247 Figure

248 Figure 1 Family Pedigree. Proband is marked by an arrow (2.1)



249



250

251

252

